Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 24, 2021updated 25 Jun 2021 1:00pm

LoA Update: Merck’s vicriviroc for metastatic colon cancer sees ten-point spike in chances to transition to next stage after Phase II completes

Merck’s vicriviroc for metastatic microsatellite stable colorectal cancer (CRC) saw its Phase Transition Success Rate (PTSR) launch 10 points to 42% after its Phase II trial completed.

Merck’s vicriviroc for metastatic microsatellite stable colorectal cancer (CRC) saw its Phase Transition Success Rate (PTSR) launch 10 points to 42% after its Phase II trial completed. The PTSR score change occurred on 21 June after ClinicalTrials.gov updated the trial from active to completed on 17 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

As to its primary endpoints, the 42-patient Phase II (NCT03631407) measured objective response rate, dose-limiting toxicities and adverse events for two doses of vicriviroc, each in combination with Merck’s Keytruda (pembrolizumab), according to ClinicalTrials.gov. Vicriviroc is a C-C Motif chemokine receptor 5 (CCR5) antagonist, which acts against HIV.

The Phase II update also resulted in a four-point bump to the drug’s Likelihood of Approval (LoA), which rose to 17%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Merck has a market cap of $192.92bn.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU